ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL...

Neuro-Oncology 2019 / 11 Vol. 21; Iss. Supplement

ATIM-44. A PHASE I FIRST-IN-HUMAN TRIAL OF TWO ADENOVIRAL VECTORS EXPRESSING HSV1-TK AND FLT3L FOR TREATING NEWLY DIAGNOSED RESECTABLE MALIGNANT GLIOMA: THERAPEUTIC REPROGRAMMING OF THE BRAIN IMMUNE SYSTEM

Lowenstein, Pedro, A Orringer, Daniel, Sagher, Oren, Heth, Jason, Hervey-Jumper, Shawn, Gerald Mammoser, Aaron, Junck, Larry, Leung, Denise, Umemura, Yoshie, Steven Lawrence, Theodore, Miran Kim, Mich
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
21
Journal:
Neuro-Oncology
DOI:
10.1093/neuonc/noz175.042
Date:
November, 2019
File:
PDF, 84 KB
2019
Conversion to is in progress
Conversion to is failed